Premium
Signalling pathway of U46619‐induced vascular smooth muscle contraction in mouse coronary artery
Author(s) -
Jiang RunSheng,
Zhang Li,
Yang Hui,
Zhou MengYuan,
Deng ChunYu,
Wu Wei
Publication year - 2021
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13502
Subject(s) - chelerythrine , myograph , protein kinase c , vasoconstriction , nifedipine , thromboxane a2 , fasudil , medicine , rho associated protein kinase , vascular smooth muscle , contraction (grammar) , channel blocker , chemistry , endocrinology , pharmacology , calcium , kinase , receptor , biochemistry , smooth muscle
Background Thromboxane A 2 (TXA 2 ) participates in many pathophysiological processes of coronary artery disease. However, its mechanism of TXA 2 ‐induced contraction in the coronary artery remains to be clarified. A multi myograph system was used to measure the isometric tension of the mouse coronary arteries and identify the effect and pathway of TXA 2 analogues U46619. Confocal laser scanning microscopy was used to measure the intracellular calcium concentration ([Ca 2+ ] i ) in mouse coronary artery smooth muscle cells. Results from the experiment had shown that contraction in coronary artery was generated by U46619 in a concentration‐dependent manner, which was completely abolished by a specific TXA 2 receptor blocker, GR32191. PI‐PLC inhibitors U73122 and D609 and Rho‐Kinase inhibitor Y‐27632 can block the U46619 elicited coronary artery contraction in a dose‐dependent manner. Then, the vasoconstriction response to U46619 was obviously inhibited by two pan‐PKC inhibitors chelerythrine or Gӧ6983, and a selective PKCδ inhibitor rottlerin, but was not blocked by a selective PKCζ inhibitor PKC‐PS or a selective PKCβ inhibitor hispidin. Meanwhile, the PKC activator PDBu‐induced vasoconstriction was significantly inhibited by 1 μmol/L nifedipine, then mostly inhibited by 100 μmol/L 2‐APB and 10 μmol/L Y27632. We further found that the response to U46619 was inhibited, respectively, by three calcium channel blockers nifedipine, SKF96356 or 2‐APB in a concentration‐dependent manner. Although Store‐operated Ca 2+ (SOC) channels generated the increase of [Ca 2+ ] i in mouse coronary artery smooth muscle cells, SOC channels did not contribute to the vasoconstriction in mouse coronary arteries. Caffeine‐induced sarcoplasmic reticulum (SR) Ca 2+ release could obviously induce coronal vasoconstriction. In addition, NPPB, a cell membrane Ca 2+ activated C1 − channel blocker, could obviously inhibit the U46619‐induced vasoconstriction. The U46619‐induced mouse coronary artery contraction was involved in the increase in [Ca 2+ ] i mediated by Cav1.2, TRPC channels and SR release through the activation of G‐protein‐coupled TP receptors and the kinases signalling pathway in TP downstream proteins, while SOC channels did not participate in the vasoconstriction.